Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
Strategies and innovations related to how clinical professionals are utilizing technology internal and external to their organizations to advance clinical trials. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
The platforms and capabilities available at this laboratory are complementary to and broaden LabCorp's existing global Clinical Trials laboratory network, and we will work to develop and expand these capabilities in the future. Equally impressive are the skills and accomplishments of the more than 50 scientists and staff who are now members of the LabCorp team.
In addition to global safety and specialty testing services, LabCorp can now offer clients a more comprehensive set of genomic services in earlier stages of drug development. The acquisition enhances LabCorp's existing biomarker development and companion diagnostics capabilities and it confirms our commitment to expand and enhance our industry-leading genomic services -- including translational biomarkers, computational biology, and next generation sequencing.
LabCorp Clinical Trials already provides a number of core genomic services -- including mutation analysis, pharmacogenetics, and pharmacogenomics -- from our global locations in North America, Belgium and China to support early- to late-phase clinical trials. This acquisition significantly expands our current offering by allowing LabCorp to provide clients with a more comprehensive set of genomic services from preclinical and early development to late-stage development.